TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT

The emergence of drug resistance is a major obstacle in the treatment of cancer patients. Here, the authors show that TRIB2 expression increases resistance to PI3K inhibition by promoting AKT activation and the subsequent FOXO inactivation and disruption of p53 function.

Guardado en:

Detalles Bibliográficos
Autores principales:	Richard Hill, Patricia A. Madureira, Bibiana Ferreira, Inês Baptista, Susana Machado, Laura Colaço, Marta dos Santos, Ningshu Liu, Ana Dopazo, Selma Ugurel, Angyal Adrienn, Endre Kiss-Toth, Murat Isbilen, Ali O. Gure, Wolfgang Link
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/176359cfd25c4c82970d73e492cb40ae
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:176359cfd25c4c82970d73e492cb40ae
record_format	dspace
spelling	oai:doaj.org-article:176359cfd25c4c82970d73e492cb40ae2021-12-02T17:06:01ZTRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT10.1038/ncomms146872041-1723https://doaj.org/article/176359cfd25c4c82970d73e492cb40ae2017-03-01T00:00:00Zhttps://doi.org/10.1038/ncomms14687https://doaj.org/toc/2041-1723The emergence of drug resistance is a major obstacle in the treatment of cancer patients. Here, the authors show that TRIB2 expression increases resistance to PI3K inhibition by promoting AKT activation and the subsequent FOXO inactivation and disruption of p53 function.Richard HillPatricia A. MadureiraBibiana FerreiraInês BaptistaSusana MachadoLaura ColaçoMarta dos SantosNingshu LiuAna DopazoSelma UgurelAngyal AdriennEndre Kiss-TothMurat IsbilenAli O. GureWolfgang LinkNature PortfolioarticleScienceQENNature Communications, Vol 8, Iss 1, Pp 1-9 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Richard Hill Patricia A. Madureira Bibiana Ferreira Inês Baptista Susana Machado Laura Colaço Marta dos Santos Ningshu Liu Ana Dopazo Selma Ugurel Angyal Adrienn Endre Kiss-Toth Murat Isbilen Ali O. Gure Wolfgang Link TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT
description	The emergence of drug resistance is a major obstacle in the treatment of cancer patients. Here, the authors show that TRIB2 expression increases resistance to PI3K inhibition by promoting AKT activation and the subsequent FOXO inactivation and disruption of p53 function.
format	article
author	Richard Hill Patricia A. Madureira Bibiana Ferreira Inês Baptista Susana Machado Laura Colaço Marta dos Santos Ningshu Liu Ana Dopazo Selma Ugurel Angyal Adrienn Endre Kiss-Toth Murat Isbilen Ali O. Gure Wolfgang Link
author_facet	Richard Hill Patricia A. Madureira Bibiana Ferreira Inês Baptista Susana Machado Laura Colaço Marta dos Santos Ningshu Liu Ana Dopazo Selma Ugurel Angyal Adrienn Endre Kiss-Toth Murat Isbilen Ali O. Gure Wolfgang Link
author_sort	Richard Hill
title	TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT
title_short	TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT
title_full	TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT
title_fullStr	TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT
title_full_unstemmed	TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT
title_sort	trib2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase akt
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/176359cfd25c4c82970d73e492cb40ae
work_keys_str_mv	AT richardhill trib2confersresistancetoanticancertherapybyactivatingtheserinethreonineproteinkinaseakt AT patriciaamadureira trib2confersresistancetoanticancertherapybyactivatingtheserinethreonineproteinkinaseakt AT bibianaferreira trib2confersresistancetoanticancertherapybyactivatingtheserinethreonineproteinkinaseakt AT inesbaptista trib2confersresistancetoanticancertherapybyactivatingtheserinethreonineproteinkinaseakt AT susanamachado trib2confersresistancetoanticancertherapybyactivatingtheserinethreonineproteinkinaseakt AT lauracolaco trib2confersresistancetoanticancertherapybyactivatingtheserinethreonineproteinkinaseakt AT martadossantos trib2confersresistancetoanticancertherapybyactivatingtheserinethreonineproteinkinaseakt AT ningshuliu trib2confersresistancetoanticancertherapybyactivatingtheserinethreonineproteinkinaseakt AT anadopazo trib2confersresistancetoanticancertherapybyactivatingtheserinethreonineproteinkinaseakt AT selmaugurel trib2confersresistancetoanticancertherapybyactivatingtheserinethreonineproteinkinaseakt AT angyaladrienn trib2confersresistancetoanticancertherapybyactivatingtheserinethreonineproteinkinaseakt AT endrekisstoth trib2confersresistancetoanticancertherapybyactivatingtheserinethreonineproteinkinaseakt AT muratisbilen trib2confersresistancetoanticancertherapybyactivatingtheserinethreonineproteinkinaseakt AT aliogure trib2confersresistancetoanticancertherapybyactivatingtheserinethreonineproteinkinaseakt AT wolfganglink trib2confersresistancetoanticancertherapybyactivatingtheserinethreonineproteinkinaseakt
_version_	1718381716367736832

TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT

Ejemplares similares